KIAA 1096, a Gene on Chromosome 1q, is Amplified and Overexpressed in Bladder Cancer

Huang, William C.; Taylor, Sherry; Nguyen, Trang B.; Tomaszewski, John E.; Libertino, John A.; Malkowicz, S.B.; Mcgarvey, Terence W.
October 2002
DNA & Cell Biology;Oct2002, Vol. 21 Issue 10, p707
Academic Journal
Chromosomal gain on 1q23-24 is a cytogenetic finding found in approximately 30% of bladder tumors. Currently, no defined or candidate tumor-associated genes from this region have been identified. The objective of this study was to identify and quantitate the expression of putative cancer genes located at this chromosome locus in normal urothelium, superficial, and muscle invasive bladder tumors. We examined both normal and bladder cancer tissue specimens (N = 40-80 RNA, DNA, and protein) by semiquantitative RT/PCR, genomic PCR, and by Western blotting. The KIAA1096 gene is located at 1q23-24 with no overexpression or amplification in normal urothelium, but was significantly upregulated in 30% of tumors (P = 0.0001). There was a trend towards increased expression in invasive compared to superficial lesions (P = 0.06). A significant increase in gene copy was also found in a 38% of TCC of the bladder compared to normal bladder mucosa or peripheral blood lymphocytes. Immunohistochemistry (IHC) demonstrated KIAA1096 expression in nonmalignant bladder mucosa tissue but apparent upregulation in invasive transitional cell carcinoma. Two other genes, CH1 and RGS5, which are situated in the same region of chromosome lq, demonstrated disparate patterns of expression. In summary, KIAAI096 is a gene situated at 1q23-24, which demonstrated a pattern of RNA and DNA expression consistent with the 38% expression of cytogenetic amplification noted on previous studies. This gene may, therefore, be a putative marker for this cytogenetic phenomenon and provide an opportunity to evaluate the clinical significance of previous cytogenetic findings.


Related Articles

  • Analysis of Her2/neu Overexpression and Amplification in Urothelial Carcinoma of the Bladder Associated with Cox-2 Overexpression. ElMoneim, Hanan Mohamed Abd; Tawfik, Heba Mohamed; El Sherbiny, Yaser Makram; Tawfiek, Ehab Rifat // International Journal of Cancer Research;2011, Vol. 7 Issue 1, p8 

    No abstract available.

  • Erratum to: New code site classification, amplification factors and normalized response spectra based on a worldwide ground-motion database. Pitilakis, Kyriazis; Riga, Evi; Anastasiadis, Anastasios // Bulletin of Earthquake Engineering;Aug2013, Vol. 11 Issue 4, p967 

    A correction to the article "New code site classification, amplification factors and normalized response spectra based on a worldwide ground-motion database," by Kyriazis Pitilakis and colleagues, published in a 2012 issue of "Bulletin Earthquake Engineering."

  • Genetic association with bladder cancer.  // British Medical Journal;9/1/1979, Vol. 2 Issue 6189, p514 

    Examines the association of genetic constitution with bladder cancer. Factors enhancing the risk of bladder cancer; Examination of the ABO antigens and HLA antigens in patients with cell carcinoma of the bladder; Association of ABO blood groups with gastrointestinal cancer.

  • p15INK4b in bladder carcinomas: decreased expression in superficial tumours. Le Frère-Belda, M A; Cappellen, D; Daher, A; Gil-Diez-de-Medina, S; Besse, F; Abbou, C C; Thiery, J P; Zafrani, E S; Chopin, D K; Radvanyi, F // British Journal of Cancer;11/15/2001, Vol. 85 Issue 10, p1515 

    The p15 gene which encodes a cyclin-dependent kinase inhibitor, is located in the 9p21 chromosomal region that is frequently deleted in human bladder transitional cell carcinomas (TCCs). The aim of the present paper is to study the potential involvement of thep15 gene in the evolution of TCCs....

  • The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Turner, K.J.; Crew, J.P.; Wykoff, C.C.; Watson, P.H.; Poulsom, R.; Pastorek, J.; Ratcliffe, P.J.; Cranston, D.; Harris, A.L. // British Journal of Cancer;4/22/2002, Vol. 86 Issue 8, p1276 

    Regulation by hypoxia may underlie the expression of vascular endothelial growth factor in bladder cancer. We have compared the distribution of vascular endothelial growth factor mRNA with a hypoxia marker, carbonic anhydrase 9 (CA IX). vascular endothelial growth factor mRNA was analysed by in...

  • Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patterns. Dangles, V.; Lazar, V.; Validire, P.; Richon, S.; Laville, V. // British Journal of Cancer;4/22/2002, Vol. 86 Issue 8, p1283 

    In order to assess the effect of in vitro models on the expression of key genes known to be implicated in the development or progression of cancer, we quantified by real-time quantitative PCR the expression of 28 key genes in three bladder cancer tissue specimens and in their derived cell lines,...

  • Rapid Assays for Quantitating Cytokine Gene Expression Without Target Amplification. Gonzales, Frank R.; Lois, Augusto; Sewell, Toddy; LaCerte, Carl; Tolley, James; Gaynor, Barbara; Garcia, Eidson; Jazdzewski, Melinda; Olivier, Tammy; Postor, Irene; Trainor, Deirdre // Combinatorial Chemistry & High Throughput Screening;Jun2003, Vol. 6 Issue 4, p293 

    Many drug discovery efforts are focused on finding candidates that alter gene expression of the cytokines involved in inflammation, allergy, and cell-mediated immunity. Current methods used to evaluate gene expression such as northern blot and RT-PCR are laborious, time-consuming, expensive, and...

  • E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. Oeggerli, M.; Schraml, P.; Ruiz, C.; Bloch, M.; Novotny, H.; Mirlacher, M.; Sauter, G.; Simon, R. // Oncogene;10/19/2006, Vol. 25 Issue 49, p6538 

    Amplification of 6p22 occurs in about 10–20% of bladder cancers and is associated with enhanced tumour cell proliferation. Candidate target genes for the 6p22 amplicon include E2F3 and the adjacent gene NM_017774. To clarify which gene is representing the main target, we compared the...

  • Altered patterns of MDM2 and TP53 expression in human bladder cancer. Lianes, Pilar; Orlow, Irene // JNCI: Journal of the National Cancer Institute;9/7/94, Vol. 86 Issue 17, p1325 

    Determines the frequency of MDM2 and TP53 gene abnormalities in bladder tumors. Patient characteristics and tissues; Monoclonal antibodies and immunohistochemistry; Southern blotting for MDM2 amplification; SSCP analysis and DNA sequencing for TP53 mutations; Altered genotype and phenotype of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics